Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 28;25(1):166.
doi: 10.1186/s12913-024-12139-w.

Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India

Ian Osoro N  1 , Suhaib Kp  1 , Jamuna Rani R  2 , Rajanandh Mg  3
Affiliations

Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India

Ian Osoro N et al. BMC Health Serv Res. .

Abstract

Introduction: Several adverse drug reactions (ADRs) go unreported within a healthcare setting despite the risks they cause. We therefore decided to conduct this study in order to recognize the obstacles that hinder the healthcare professionals (HCPs) in a tertiary care hospital in Kattankulathur, Tamil Nadu from reporting ADRs and what strategies ought to be implemented.

Methods: We carried out a cross-sectional study among the HCPs such as doctors, pharmacists and nurses within our institution. A pre-validated questionnaire was used to collect data on the socio-demographics, barriers and facilitators in reporting ADR. A 2 weeks timeline was given to the HCPs to fill the questionnaire forms. Out of the 107 forms distributed, we received 80 of them that were duly filled. Data was analyzed using IBM SPSS version 26.

Results: Out of the 80 HCPs, only 22 of them had reported any ADRs in their career. 52% of our HCPs reported the lack of understanding of ADR reporting mechanism as their main hindrance. Additionally, 25 (31%) of the HCPs stated that reporting ADRs is time consuming. 18 (22%) of them reported a fear of legal liability. 13 (16%) of them stated that the reporting from is complicated and 29 (36%) stated a lack of motivation as the reason for not reporting ADR. Majority of our HCPs 76 (95%) recommended the need for continuous medical education and training as the best strategy to improve ADR reporting.

Conclusion: Barriers such as time constraints, workload pressures and competing priorities often hinder HCPs from dedicating adequate attention to ADR reporting. The inclusion of topics related to ADR reporting in the curriculum (i.e. clinical pharmacology) and increased awareness from the ADR monitoring centre were seen to be significant facilitators to enhance ADR reporting among health care practitioners.

Keywords: Adverse drug reaction; Clinical pharmacy; Nurses; Pharmacovigilance; Physicians.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study protocol was approved by the Institutional Ethics Committee of SRM Medical College Hospital and Research Centre, SRM ISR, Kattankulathur, Tamil Nadu, India (Ref No: SRMIEC-ST0923-630). Written informed consent was obtained from the study participants and the study was conducted according to the revised National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, Indian Council of Medical Research (ICMR) 2017. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Barriers in reporting ADRs
Fig. 2
Fig. 2
Facilitators on reporting ADRs
See this image and copyright information in PMC

References

    1. Kalaiselvan V, Srivastava S, Singh A. Pharmacovigilance in India: Present Scenario and Future Challenges. Drug Saf. 2019;42(3):339–46. 10.1007/s40264-018-0730-7. PMID: 30269244. - PubMed
    1. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–56. 10.1002/bdrc.21096. Epub 2015 Jun 4. PMID: 26043938; PMCID: PMC4737249. - PMC - PubMed
    1. Klein E, Bourdette D. Postmarketing adverse drug reactions: A duty to report? Neurol Clin Pract. 2013;3(4):288–94. 10.1212/CPJ.0b013e3182a1b9f0. PMID:24195018;PMCID:PMC3787113. - PMC - PubMed
    1. Craigle V. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. J Med Libr Assoc. 2007;95(2):224–5. 10.3163/1536-5050.95.2.224. PMCID:PMC1852611.
    1. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7. 10.4103/0976-500X.120957. PMID:24347988;PMCID:PMC3853675. - PMC - PubMed

LinkOut - more resources